Definium Therapeutics (NASDAQ:DFTX) Sets New 12-Month High – Here’s What Happened

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $21.55 and last traded at $21.55, with a volume of 28757 shares trading hands. The stock had previously closed at $20.58.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Definium Therapeutics in a research report on Monday, February 2nd. Wolfe Research assumed coverage on shares of Definium Therapeutics in a research report on Monday, February 23rd. They issued an “outperform” rating and a $25.00 price objective for the company. Royal Bank Of Canada lifted their price objective on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Jefferies Financial Group assumed coverage on shares of Definium Therapeutics in a research report on Thursday, January 29th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, HC Wainwright lifted their price objective on shares of Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $35.70.

Definium Therapeutics Stock Up 2.1%

The firm has a market cap of $2.09 billion, a P/E ratio of -9.86 and a beta of 2.44. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.29 and a current ratio of 6.29. The firm’s fifty day moving average is $17.88 and its 200 day moving average is $14.57.

Institutional Trading of Definium Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its holdings in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the period. BIT Capital GmbH bought a new stake in shares of Definium Therapeutics during the 3rd quarter worth about $26,000. Fifth Third Bancorp boosted its holdings in shares of Definium Therapeutics by 5,593.2% during the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after buying an additional 3,300 shares during the period. Sound Income Strategies LLC bought a new stake in shares of Definium Therapeutics during the 3rd quarter worth about $46,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Definium Therapeutics by 56.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after buying an additional 3,020 shares during the period. Institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.